SCHEMBL4925908

SCHEMBL4925908

Cc1ccc(-c2ccccc2OCc2ccccc2)cc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 4/20 0.49
TLR7 Q9NYK1 2/20 0.49
MCL1 Q07820 1/20 0.46
ALK Q9UM73 1/20 0.45
ACHE P22303 1/20 0.45
GPR119 Q8TDV5 3/20 0.45
CCNT1 O60563 1/20 0.45
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
CDK9 P50750 1/20 0.45
CCNA1 P78396 1/20 0.45
KIT P10721 1/20 0.44
SMARCA2 P51531 1/20 0.44
SMARCA4 P51532 1/20 0.44
PBRM1 Q86U86 1/20 0.44
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
YAP1 P46937 2/20 0.43
PRMT5 O14744 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4922449 0.84 KDM4E (0.51) TLR9TLR7
SCHEMBL5339319 0.82 HTR1A (0.55) TLR9TLR7ACHEGPR119CKS1B
SCHEMBL4927170 0.81 SMARCA2 (0.61) GPR119KITSMARCA2SMARCA4PBRM1
SCHEMBL4921870 0.81 HTR6 (0.61) TLR9TLR7ACHEGPR119CKS1B
SCHEMBL5577222 0.80 KIT (0.39) ALKGPR119KITSMARCA2SMARCA4
Hydrochloric Acid SCHEMBL4928899 0.79 HTR6 (0.61) MCL1
SCHEMBL24514502 0.79 SMARCA2 (0.71) TLR9TLR7ACHEGPR119CCNT1
SCHEMBL17658994 0.78 GPR119 (0.54) TLR9TLR7ACHEGPR119KIT
SCHEMBL20521485 0.77 TLR9 (0.52) TLR9TLR7ACHEGPR119CCNT1
SCHEMBL31443646 0.77 TLR9 (0.50) TLR9TLR7ALKACHEGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076338-B2 Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation EXELIXIS, INC. (US) 2011-12-13 US disclosed
US-20080076774-A1 Kinase Modulators and Methods of Use EXELIXIS, INC. (US) 2008-03-27 US disclosed
EP-1750727-A2 KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2007-02-14 EP disclosed
WO-2005117909-A2 KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076774-A1 Kinase Modulators and Methods of Use AKT3, RPS6KA3, CDK3 TLR9 2256/4885TLR7 3161/4885MCL1 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.